Wyeth drops Karo Bio atherosclerosis drug

Karo Bio and research partner Wyeth Pharmaceuticals have abandon development of LXR-623, a Phase I compound for atherosclerosis. According to a release, LXR-623 demonstrated efficacy on biomarkers for atherosclerosis but had an unfavorable profile for further development. However, the companies say they will continue their partnership on Liver X Receptor (LXR), with the aim to develop new treatments for atherosclerosis.

"Unfortunately, compounds do fail in the process but this is part of the development of pharmaceuticals. We remain optimistic about LXR as a target for treatment of atherosclerosis and for the prospects for new molecules for development. The learnings generated from the LXR-623 program will be valuable as additional potential compounds move forward," noted Per Olof Wallström, President of Karo Bio.

- see the release for more

Related Article:
Merck pulls out of Karo Bio collaboration. Report

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.